[HTML][HTML] Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction
P Tyrna, G Procyk, Ł Szeleszczuk… - … Journal of Molecular …, 2024 - pmc.ncbi.nlm.nih.gov
Proteasome inhibitors (PIs), bortezomib, carfilzomib, and ixazomib, are the first-line
treatment for multiple myeloma (MM). They inhibit cytosolic protein degradation in cells …
treatment for multiple myeloma (MM). They inhibit cytosolic protein degradation in cells …
Advances in research on potential inhibitors of multiple myeloma
G Tang, S Huang, J Luo, Y Wu, S Zheng, R Tong… - European Journal of …, 2023 - Elsevier
Multiple myeloma (MM) is a common hematological malignancy. Although recent clinical
applications of immunomodulatory drugs, proteasome inhibitors and CD38-targeting …
applications of immunomodulatory drugs, proteasome inhibitors and CD38-targeting …